Patient perspectives of migraine symptomology: Insights from exit interviews from the anti-PACAP antibody phase 2 HOPE trial for migraine prevention

Authors
Category Primary study
Conference67th Annual Scientific Meeting
Year 2025
This article has no abstract
Epistemonikos ID: 8ced25dadf9318c9a124e8e705c34c2f611586a5
First added on: Apr 04, 2026